Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2001-03-15
2004-05-11
Cook, Rebecca (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C424S649000
Reexamination Certificate
active
06734178
ABSTRACT:
FIELD OF THE INVENTION
The technical field of the invention is the use of cephalotaxine alkaloids with antiproliferative agents to treat a host with a cellular proliferative disease.
BACKGROUND OF THE INVENTION
There is considerable interest in modulating the efficacy of currently used antiproliferative agents to increase the rates and duration of antitumor effects associated with conventional antineoplastic agents.
Conventional antiproliferative agents used in the treatment of cancer are broadly grouped as chemical compounds which (1) affect the integrity of nucleic acid polymers by binding, alkylating, inducing strand breaks, intercalating between base pairs or affecting enzymes which maintain the integrity and function of DNA and RNA; (2) chemical agents that bind to proteins to inhibit enzymatic action (e.g., antimetabolites) or the function of structural proteins necessary for cellular integrity (e.g., antitubulin agents). Other chemical compounds that have been identified to be useful in the treatment of some cancers include drugs which block steroid hormone action for the treatment of breast and prostate cancer, photochemically activated agents, radiation sensitizers and protectors.
Of special interest to this invention are those compounds that directly affect the integrity of the genetic structure of the cancer cells. Nucleic acid polymers such as DNA and RNA are prime targets for anticancer drugs. Alkylating agents such as nitrogen mustards, nitrosoureas, aziridine containing compounds directly attack DNA. Metal coordination compounds such as cisplatin and carboplatin similarly directly attack the nucleic acid structure resulting in lesions that are difficult for the cells to repair which, in turn, can result in cell death. Other nucleic acid affecting compounds include anthracycline molecules such as doxorubicin, which intercalates between the nucleic acid base pairs of DNA polymers, bleomycin which causes nucleic acid strand breaks, and fraudulent nucleosides. Fradulent nucleosides include pyrimidine and purine nucleoside analogs which are inappropriately incorporated into nucleic polymer structures and ultimately cause premature DNA chain termination. Certain enzymes that affect the integrity and functionality of the genome can also be inhibited in cancer cells by specific chemical agents and result in cancer cell death. These include enzymes that affect ribonucleotide reductase (e.g. hydroxyurea, gemcitabine), topoisomerase I (e.g. camptothecin) and topoisomerase II (e.g., etoposide).
One of the most broadly used of these DNA targeted anticancer drugs is cisplatin (cis-diamminedichloroplatinum II, CDDP). This compound is active against several human cancers including testicular, small-cell lung, bladder, cervical and head and neck cancer.
Although the clinical activity of currently approved antiproliferative agents against many forms of cancers can be shown, improvements in tumor response rates, duration of response and ultimately patient survival are still sought. The invention described herein demonstrates the novel use of the cephalotaxine alkaloids and analogs thereof, including homoharringtonine (HHT) which can potentiate the antitumor effects of chemotherapeutic drugs, in particular, agents affecting the integrity of nucleic polymers such as DNA.
SUMMARY OF THE INVENTION
Methods and compositions are provided for the treatment of a host with a cellular proliferative disease, particularly a neoplasia. In the subject methods, pharmaceutically acceptable cephalotaxine and an antiproliferative agent are administered in an amount sufficient to modulate the cellular proliferative disease.
REFERENCES:
patent: WO 2001068098 (2001-09-01), None
Jin et al., Shanghai Yike Daxue Xuebao (1989), 16(1), 50-4 Abstract Only.*
Abbott et al., Cancer Research Supplement, Part 2, vol. 26, No. 9, Sep., 1966, pp 1131, 1132, 1135 and 1136.*
Visani, C., et al., “Effects of homoharringtonine alone and in combination with alpha interferon and cytosine with alpha interferon and cytosine arabinoside on “in vitro” growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors,”Leukemia11:624-628 (1997).
Yuzhu, Z. et al., “Hemoharringtonine, cytarabine and aclarubicin (HAA) combination chemotherapy for acute myeloid leukemia (AML),” Chinese Journal of Clinical Oncology (1998) 25/10 pp. 758-759, retrieved from STN, Database EMBASE ‘Online’ Acc. No. 1998384948 Abstract.
Laster Jr., W.R. et al., “Therapeutic synergism (TS) of homoharringtonine (H) plus 5-fluorouracil (FU) against leukemia P388 (P388/o) and ARA-C-resistant P388 (P388/ARA-C),” Proc. Am. Assoc. Cancer Res. (1982), vol. 23, No. 786. retrieved from STN, Database EMBASE ‘Online’ Acc. No. 82182588.
Zhang, S.D. et al., “Inhibitory Effects of Homoharringtonine and Hydroxycamptothecin in Combination with Other Agents on Cancer Cell Growth,”Asia Pacific Jour Pharm1992, 7:191-195.
Takano, I. et al., “New Oxygenated Cephalotaxus Alkaloids fromCephalotaxus harringtoniavar.drupacea,” J. Nat. Proc.1996, 59:1191-1195.
Takano, I. et al., “Ester-Type Cephalotaxus Alkaloids fromCephalotxus Harringtoniavar.Drupacea,” Phytochemistry44(4):735-738 (1997).
Chemgenex Therapeutics, Inc.
Cook Rebecca
Dorsey & Whitney LLP
Ropp Traci H.
Trecartin Richard F.
LandOfFree
Cephalotaxine alkaloid compositions and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cephalotaxine alkaloid compositions and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cephalotaxine alkaloid compositions and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3214226